Answers are grounded in this paper and cite their sources.
Identifying safe and effective CAR T cell targets in acute myeloid leukemia (AML) is challenging due to the disease’s complexity and overlap with normal hematopoiesis. This review highlights advances in target discovery for AML, emphasizing innovative approaches. Structural surfaceomics identifies tumor-specific protein conformations, while AI-driven single-cell RNA sequencing integrates multi-source data to pinpoint optimal targets. Refined cell surface capture technology maps the AML surfaceome without relying on predefined antibodies. These strategies enhance CAR T cell specificity and minimize off-tumor effects, offering promising pathways for safer and more effective AML treatments and broader cancer therapies. • Mass spectrometry-based methods reveal AML-specific surface proteins, offering unbiased target identification. • Structural surfaceomics identifies tumor-specific protein conformations, improving the specificity of CAR T cells. • Integrating proteomics with transcriptomics refines target selection by excluding antigens expressed on healthy tissues. • AI-powered single-cell RNA sequencing enhances target discovery, improving specificity and minimizing on-target effects. • Surfaceomics integrating single-cell RNA sequencing and surface proteomics identify novel pan-AML and AML subtype markers.
No takes yet. Share an insight, caveat, or question.
Hoffmann et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: